Oxford BioMedica to Present at Conference

RNS Number : 0136L

Oxford Biomedica PLC

29 August 2012

 



 Oxford BioMedica to Present at the 2012 Rodman & Renshaw Annual Global Investment Conference

-- 14^th Annual Healthcare Conference --

Oxford, UK - 29 August 2012: Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB), the leading gene-based biopharmaceutical company, today announces that John Dawson, Chief Executive Officer of Oxford BioMedica, will present at the Rodman & Renshaw Annual Global Investment Conference to be held on September 9-11, 2012 at The Waldorf Astoria, NY (USA).

The presentation is scheduled for Monday, 10 September 2012 at 16:30 Eastern Time.  A copy of the slide presentation will be made available on the "Investors/Corporate presentations" section of the Company's website at www.oxfordbiomedica.co.uk.

-Ends-

For further information, please contact:
Oxford BioMedica plc: Lara Mott, Head of Corporate Communications	Tel: [phone]
Media Enquiries: Mary Clark/Sarah Macleod/Claire Dickinson M:Communications	Tel: [phone]

Notes to editors

1. Oxford BioMedica^®

Oxford BioMedica plc (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs.  The Company's technology platform includes a highly efficient LentiVector^® gene delivery system, which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy.  Through in-house and collaborative research, Oxford BioMedica has a broad pipeline with current partners and licensees including Sanofi, Pfizer, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions and ImaginAb.  Further information is available at www.oxfordbiomedica.co.uk.

 

END

 

 

NRAUKOURUSAWUAR